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Abstract 
Activation-induced cytidine deaminase (AID) is essential for the somatic 
hypermutation (SHM) and class switch recombination (CSR) of immunoglobulin 
genes. The mechanism by which AID triggers SHM and CSR has been explained by 
two distinct models. In the DNA deamination model, AID converts cytidine bases in 
DNA into uridine. The uridine is recognized by the DNA repair system, which 
produces DNA strand breakages and point mutations. In the alternative model, RNA 
edited by AID is responsible for triggering CSR and SHM. However, RNA 
deamination by AID has not been demonstrated. Here we found that C-to-T and 
G-to-A mutations accumulated in the hepatitis B virus (HBV) nucleocapsid DNA 
when AID was expressed in HBV-replicating hepatic cell lines. AID expression 
caused C-to-T mutations in the nucleocapsid DNA of RNase H-defective HBV, which 
does not produce plus-strand viral DNA. Furthermore, the RT-PCR products of 
nucleocapsid viral RNA from AID-expressing cells exhibited significant C-to-T 
mutations, whereas viral RNAs outside the nucleocapsid did not accumulate C-to-U 
mutations. Moreover, AID was packaged within the nucleocapsid by forming a 
ribonucleoprotein complex with HBV RNA and the HBV polymerase protein. The 
encapsidation of the AID protein with viral RNA and DNA provides an efficient 
environment for evaluating AID’s RNA and DNA deamination activities. A bona fide 
RNA-editing enzyme, APOBEC1, induced a similar level of C-to-U mutations in 
nucleocapsid RNA as AID. Taken together, the results indicate that AID can 




Antigen-induced immunoglobulin diversification is the basis of antibody memory, 
which is critical for effective vaccination. Activation-induced cytidine deaminase 
(AID) is required for somatic hypermutation (SHM) and class switch recombination 
(CSR), both of which are initiated by DNA cleavage induced by AID (1-4). The 
molecular mechanism by which AID triggers DNA cleavage specifically in 
immunoglobulin loci is a key question for understanding acquired immunity. There 
are two hypotheses for explaining how AID initiates DNA cleavage at the 
immunoglobulin locus: the DNA deamination model and the RNA editing hypothesis.  
The DNA deamination model is based on the observation that AID induces 
mutations in the genomic DNA of E. coli and deaminates dC in single-stranded DNA 
in vitro (5-8). The resulting dU/dG mismatches are proposed to be recognized by 
enzymes in the base excision repair pathway, which cleave the DNA phosphodiester 
bond. However, it has not been directly demonstrated that AID generates dU 
specifically in the immunoglobulin locus. By contrast, in the RNA editing hypothesis, 
AID deaminates RNA, and the edited RNA is involved in DNA cleavage at the 
immunoglobulin genes (4, 9). This model was initially based on the structural 
similarity of AID with apolipoprotein B mRNA editing catalytic polypeptide 1 
(APOBEC1), which is a bona fide RNA-editing enzyme (3, 4). Subsequently, various 
AID mutants were shown to have distinct defects in either CSR or SHM, suggesting 
that AID has at least two functions: one (DNA cleaving activity) shared by SHM and 
CSR and the other (DNA end-repairing activity) specific to CSR (9). The latter 
activity is dependent on the translation of a new protein (10). In addition, AID’s 
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C-terminal region interacts with poly A-containing RNA (11). However, neither RNA 
deamination activity nor a target RNA have been demonstrated for AID. 
HBV is a small DNA virus whose replication depends on reverse transcription 
(Fig. S1). To study the deaminase activity of AID against HBV, we used an in vitro 
model of HBV viral replication, in which an HBV replicon plasmid is transfected into 
a human hepatocyte cell line such as HepG2 or Huh7.  The HBV replicon plasmid 
carries the full viral genomic sequence with an additional epsilon () sequence (Fig. 
S2). After transfection, the replicon plasmid transcribes all the viral genes necessary 
for its replication, including pregenomic (pg) RNA and the mRNAs for viral proteins 
(P, core, X, and S) (Fig. S1A, left). The core protein encapsidates pgRNA to form a 
nucleocapsid, where the P protein reverse transcribes pgRNA to produce minus-strand 
DNA (Fig. S1B and C). The P protein digests the pgRNA in the RNA/DNA hybrid 
through its RNase H activity (Fig. S1D), and synthesizes plus-strand DNA to generate 
relaxed circular (RC) DNA in the nucleocapsid (Fig. S1E). Finally, the nucleocapsid 
is secreted as a virion after acquiring surface proteins. A small fraction of the 
nucleocapsid is transferred to the nucleus, where RC-DNA is released from the 
nucleocapsid and converted to covalently closed circular (ccc) DNA. In HBV 
infections in vivo, the cccDNA accumulates and remains in the nucleus of hepatocytes, 
where it serves as a transcription template for all the viral RNAs. The X gene encodes 
a protein that is not essential for viral replication, but may play a role in the 
development of hepatocellular carcinomas (12, 13). 
AID belongs to the APOBEC (A) protein family. In humans, this family has at 
least 11 members: AID, A1, A2, A3A, A3B, A3C, A3DE, A3F, A3G, A3H, and A4 (14, 
15). Recently, A3G was reported to induce hypermutation in the HBV nucleocapsid 
DNA. A3G is encapsidated with and hypermutates viral DNA (16). Rosler et al. 
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reported that the overexpression of A1 results in hypermutation not only in the viral 
DNA but also in the viral RNA of HBV (17). Bishop et al. found that C-to-U 
mutations accumulated in HIV-1 viral RNAs produced in the presence of A1 (18). 
More recently, Vartanian et al. suggested that AID has HBV hypermutation activity at 
a comparable level to that of A3G in vitro (19). Since A1 deaminates both viral RNA 
and DNA, we were interested in whether AID also deaminates HBV RNA. 
In this study, using the in vitro HBV replication model, we found that the AID 
protein associates physically with the P protein and HBV RNA. Furthermore, AID 
deaminates C in viral RNA and causes C-to-U mutations in nucleocapsid RNA.  
These data demonstrate that AID can directly deaminate C in viral RNA.
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Results  
AID caused G-to-A and C-to-T hypermutation in RC-DNA 
 To examine AID-induced hypermutation in the HBV viral genome, a human 
AID expression vector and an HBV replicon plasmid (pHBV1.5 (20)) (Fig. S2A) 
were transfected into a human hepatic cell line (HepG2).  Transfection with the HBV 
replicon plasmid initiated HBV viral replication and reproduced the intracellular viral 
life cycle in the HepG2 cells. Three days after transfection, the cells were lysed, 
treated with DNase I to eliminate residual transfected plasmids, and the nucleocapsids 
were then purified from the cytoplasmic lysates. The nucleocapsids were digested by 
proteinase K in the presence of SDS to isolate RC-DNA. The purified RC-DNA was 
subjected to a 3D-PCR assay of the X gene (21) because the X gene region is a good 
target of APOBEC deaminases (22). 
In 3D-PCR, hypermutated DNA can be selectively amplified by lowering the 
denaturation temperature in a PCR protocol, because hypermutated DNA has a high 
content of A/T bases and melts at a lower temperature.  Therefore, amplification of 
PCR target at lower denaturation temperatures indicates the presence of hypermutated 
DNA in a given sample.  As shown in Fig. 1A, the RC-DNA samples isolated from 
AID-expressing cells exhibited clear PCR amplification bands at lower denaturation 
temperatures than the GFP-expressing control samples, consistent with a previous 
report (19). 
To quantify the mutation frequency, samples of RC-DNA were sequenced.  
The X gene fragments in the RC-DNA were amplified from AID- or GFP-expressing 
samples using a standard PCR protocol (denaturation = 94C) and cloned into the T 
vector. From each group, 55 clones were randomly selected and sequenced.  The 
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RC-DNAs from the AID transfectants contained 15 G-to-A and 10 C-to-T mutations, 
whereas the RC-DNA samples from the GFP transfectants contained only a single 
G-to-A mutation (Fig. 1B). Similar results were obtained in two independent 
experiments using a hepatic cell line (Huh7) stably expressing HBV (Fig. S3) and 
HepG2 cell lines stably expressing AID-estrogen receptor (ER) fusion proteins (Fig. 
2).  Transfectants of the human hepatic cell line (HepG2) expressing AID-ER were 
established by retrovirus-mediated gene transduction, followed by drug selection. The 
AID-ER fusion protein was expressed as an inactive form that was activated by the 
addition of tamoxifen (4-OHT) (10). 3D-PCR of the purified RC-DNA showed 
amplified bands at lower temperatures (85.3° and 83.9°C) 6 hours after 4-OHT 
stimulation in human and mouse AID-ER transfectants (Fig. 2C). In contrast, 3D-PCR 
of the mock-ER transfectants did not produce signals at 85.3° and 83.9°C, indicating 
that stimulated AID-ER transfectants specifically induced hypermutation. To verify 
that AID-inducing hypermutation was dependent on its deaminase activity, we used a 
mutant AID (P19) that lacks deaminase activity due to a mutation in its catalytic 
domain (23), and found that it did not induce hypermutation (Fig. 2C).  
The X gene segments were cloned from the band amplified at 83.9C (Fig. 2C, 
indicated with an open box), which should contain AT-rich DNA due to deamination. 
Interestingly, in each of six randomly picked-up clones, the mutations were 
exclusively G-to-A or C-to-T, but not a mixture of both (Figs. 2D and 2E).  
Considering the mutation frequency (3.6×10
-3
) in non-enriched clones (Fig. 1B), the 
massive accumulation of G-to-A and C-to-T mutations in the single clone must be 
rare events which were detected only after enrichment by 3D-PCR.  Exclusive 
G-to-A or C-to-T hypermutation pattern suggests that the deamination reaction 
probably took place processively and only once, at either the RNA, the minus-strand 
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DNA, or the plus-strand DNA (Fig. S1). However, the efficiency of deamination of 
plus-strand DNA is considered to be much lower than that of the others, because the 
region of plus-strand DNA in RC-DNA is normally double-stranded (12, 13).  
Previous in vitro experiments showed that single-stranded DNA but not a DNA/RNA 
hybrid or double-stranded DNA can serve as a substrate for the AID, A1, or A3 
deaminase (24, 25). 
Absence of AID-induced deamination in replicon plasmid and non-encapsidated 
viral RNA 
The frequent C-to-T mutations in AID-expressing RC-DNA samples (Fig. 1B) 
suggested that pgRNA may be deaminated by AID. We therefore carried out a series 
of experiments to examine whether pgRNA could be deaminated by AID. First, we 
determined the mutation load of non-encapsidated HBV transcripts. The X gene 
segment was amplified from HBV cDNA using the standard PCR protocol 
(denaturation = 94C). If transfected replicon plasmid was directly deaminated by 
AID, transcripts from the plasmid should also show sign of hypermutation.  
However, as shown in Fig. 1C, sequencing of the cDNA derived from the 
AID-expressing HepG2 cells revealed no C-to-U mutations. Therefore, the transfected 
replicon plasmid and non-encapsidated viral RNA probably were not deaminated by 
AID. It is important to note that the encapsidated pgRNA was excluded by the organic 
RNA extraction method employed here, because it was packaged tightly in the 
nucleocapsid and removed with the protein fraction during the organic extraction. 
AID deaminated HBV transcripts in the nucleocapsid 
To examine whether the AID-induced hypermutation was due to deamination 
of the RC-DNA plus strand as suggested for A3G (26), an RNase H mutant replicon 
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(pHBV-RNase H) (Fig. S2B) was used. A single amino acid replacement in the 
RNase H domain of the P protein causes the loss of its RNase H activity while 
maintaining its DNA polymerase activity (27). Thus, the viral life cycle of 
HBV-RNase H transfectants stalls at the RNA/DNA hybrid stage in the nucleocapsid, 
and it cannot efficiently generate the RC-DNA plus strand (Fig. S1C) (27, 28).   
Southern blot analysis of the wild-type HBV after RNase H digestion revealed 
two bands, corresponding to the RC-DNA and the single-stranded (minus) DNA (Fig. 
S4, lane 2). By contrast, the RNase H-defective virus showed only a single band 
corresponding to the single-stranded DNA after RNase H digestion (Fig. S4, lane 4), 
indicating that most of the nucleocapsid viral genome in the mutant virus stalled at the 
DNA/RNA hybrid step, as shown before (27, 28). 
Using the HBV-RNase H replicon plasmid, the mutation load of the X gene 
fragment in the nucleocapsid DNA was determined as described above.  The control 
GFP expression showed no C-to-T hypermutation per 9185 bases, while the X gene 
fragment in the AID transfectants contained 4 C-to-T mutations per 9185 bases (Fig. 
3A).  The relative frequency of G-to-A hypermutation was lower than that in 
wild-type HBV (Fig. 1B). RNase H activity may be required for efficient 
hypermutation in minus-strand RC-DNA, because minus-strand DNA exists as a 
DNA/RNA hybrid in the RNase H-defective HBV.  
The detection of C-to-T mutations in the nucleocapsid DNA from 
pHBV-RNase H transfectants (Fig. 3A) and the absence of C-to-U mutations in 
HBV transcripts outside the nucleocapsid (Fig. 1C) suggested that AID may 
deaminate viral transcripts after encapsidation.  Thus, we directly analyzed the 
encapsidated viral RNA.  The pHBV-RNase H replicon plasmid was transfected 
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into Huh7 cells with the AID (or GFP) expression vector, and the cells were treated 
with an HBV polymerase inhibitor (lamivudine) to completely inhibit leaky DNA 
synthesis of plus and minus-strands (Fig. S1B).  Blocking the viral DNA synthesis 
by lamivudine is also effective for purifying the encapsidated RNA, because DNase I 
treatment may not completely digest the DNA strand of the RNA/DNA hybrid (29). 
The inhibition of RC-DNA synthesis by lamivudine was demonstrated by Southern 
blotting using native agarose gel electrophoresis (NAGE) with alkaline treatment (Fig. 
3B).   
The purified nucleocapsid RNA was reverse transcribed, and its cDNA was 
subjected to the 3D-PCR assay to detect the presence of C-to-U mutations in the X 
gene fragment from AID-, A1-, and A3G-expressing cells. The results demonstrated 
that the X gene fragment was amplified at a slightly lower denaturation temperature in 
the AID- and A1-expressing samples (Fig. 3C, right) compared with the GFP and A3G 
controls.  To identify the mutations, the PCR fragments amplified at the lower 
denaturation temperature (87.8C) were cloned and sequenced. As expected, C-to-U 
mutations were dominant in the A1- and AID-expressing samples (Fig. 3D), 
indicating that A1 and AID deaminated viral RNA.  A3G did not induce 3D-PCR 
bands at lower temperatures than GFP, indicating the absence of viral RNA 
deamination. 
We further confirmed that C-to-U mutations were derived from encapsidated 
RNA by removing the free viral RNAs outside the nucleocapsid, by 
immunoprecipitation (IP) using an anti-core antibody. The nucleocapsid RNA in the 
IP fraction and viral RNAs in the flow-through fraction were extracted after 
proteinase K digestion in the presence of SDS.  RC-DNA and plasmid DNA, if 
present, were digested with DNase I before reverse transcription. The 
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reverse-transcribed viral RNAs were subjected to the 3D-PCR assay. The results 
showed that the X gene fragment was amplified at lower denaturation temperatures in 
the AID-expressing IP fraction but not in the GFP-expressing IP or flow-through 
fractions (Fig. 4A). DNA sequencing of the 87.3C-amplified DNA band revealed 
C-to-U mutations almost exclusively (Figs. 4B and 4C), indicating that the 
nucleocapsid RNA was an RNA editing target of AID. The positions of the C-to-U 
mutations caused by AID were not highly specific but clustered near the tandem array 
of C (Fig. 4C).  Taken together, these data indicate that AID deaminates 
nucleocapsid RNA. 
AID incorporation into HBV nucleocapsids  
 To understand how AID interacts with nucleocapsid RNA, we examined the 
encapsidation of the AID protein.  Since A3G is packaged into the HBV nucleocapsid 
in a P protein-dependent manner (30), we used A3G as a control for encapsidation. 
FLAG-tagged A3G, GFP, or non-tagged AID vectors were co-transfected into 293T 
cells together with an HBV replicon plasmid (pPB). The pgRNA’s transcription in 
pPB was controlled by the CMV promoter (Fig. S2C) (31).  Proteins associated with 
the nucleocapsid were then immunoprecipitated using an anti-core antibody. As 
shown in Fig. 5A, AID and A3G were co-immunoprecipitated with the nucleocapsid 
core protein. In contrast, control GFP was not immunoprecipitated, indicating that the 
physical association between AID and the nucleocapsid proteins was specific. Similar 
results were obtained in independent experiments using two hepatic cell lines (Huh7 
and HepG2) (Figs 5B and 5C). We also tested whether AID physically associates with 
the P protein. 293T cells were co-transfected with expression vectors for the AID and 
FLAG-tagged P proteins. As shown in Fig. 5D, AID was co-immunoprecipitated with 
 12 
the FLAG-tagged P protein, indicating that AID interacts with the P protein in the 
absence of the core protein and pgRNA.  
Physical association of AID with HBV RNA 
We previously demonstrated that the AID protein binds RNA (11). Therefore, we 
tested whether AID associates with viral RNA. The AID expression vector and HBV 
replicon plasmid were transfected into Huh7 cells.  The protein-RNA complex was 
immunoprecipitated with an anti-AID antibody, and the IP fraction was divided into 
two aliquots for western blotting and RT-PCR analysis. Western blotting confirmed 
the successful IP of the AID protein (Fig. 5E, right). RT-PCR of the IP fraction with 
the AID antibody demonstrated that the HBV RNA was associated with AID, whereas 
HPRT mRNA was not precipitated with the anti-AID antibody (Fig. 5E, left). The IP 
fraction produced using control IgG did not contain HBV transcripts or HPRT mRNA 
(lane 3 in Fig. 5E, left). These results indicated that there was a physical association 
between the AID protein and the HBV RNAs. The physical association of the AID 
protein with the core and P proteins, as well as with the HBV RNAs, suggested that 
AID forms a ribonucleoprotein (RNP) complex with HBV viral proteins and RNA 
during nucleocapsid assembly (Fig. S1A). This study did not determine whether any 
of these interactions were direct or indirect, or which HBV transcripts were 
components of the RNP complex. However, it is likely that AID associates with viral 
RNA such as pgRNA through an interaction with the P protein, since the P protein 
binds pgRNA through the packaging signal, i.e., epsilon (12). 
Endogenous AID induced HBV hypermutation in B cells 
To determine whether the endogenous AID protein could induce HBV hypermutation, 
the HBV replicon plasmid (pPB) or a replication-defective replicon plasmid (pPB-P) 
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(Fig. S2D) was introduced into a human EBV-transformed B cell line (BL2 cells), in 
which somatic hypermutation in Ig genes can be continuously induced (32). pPB-P 
has a frameshift mutation in the spacer domain of the P protein, which cannot support 
viral replication (30). The GFP expression vector was transfected at the same time to 
monitor the transfection efficiency. Southern and Western blotting analyses using the 
NAGE assay demonstrated that BL2 cells could support HBV nucleocapsid formation 
(Fig. 6A). The production of RC-DNA in the nucleocapsid was completely dependent 
on the polymerase activity of the P protein (Fig. 6A, left). The transfection of pPB into 
AICDA-proficient and -deficient BL2 cells resulted in the production of RC-DNA in 
both, although the AICDA-proficient cells had a lower signal intensity for 
nucleocapsid DNA (Fig. 6A, right).  
The RC-DNAs were then purified from both the AICDA-proficient and 
-deficient BL2 cells, and 3D-PCR analysis was performed. The X gene fragments 
from the AICDA-proficient cells were amplified at a lower denaturation temperature 
(83C) than those from the AICDA-deficient ones (87.2C) (Fig. 6B). The X gene 
segments obtained using the standard PCR protocol (94C) were then cloned and 
sequenced to estimate the mutation frequency (Fig. 6C). The mutations were 
predominantly targeted at G and C, and C-to-T and G-to-A mutations were dominant. 
C-to-T mutations accumulated in the RC-DNA from the AICDA-proficient cells. The 
mutation preferences in the BL2 cells were consistent with those of the 
AID-overexpressing hepatic cell lines (Fig. 1B). The AICDA-deficient cells showed 
background levels of G-to-A and C-to-T mutations, which could be due to other 
endogenous APOBEC deaminases or to rTaq error.  Semi-quantitative RT-PCR 
showed that BL2 cells expressed most of the AID/APOBEC deaminases (Fig. S5). 
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These results indicated that endogenous AID also induced HBV hypermutation in B 
cells.   
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Discussion 
  In this study, we expressed AID in HBV-replicating cells to evaluate the target of 
the AID deaminase activity. We found that AID forms an RNP complex with viral 
RNA as well as the core and P proteins. The X gene segment of RC-DNA 
accumulated C-to-T mutations, which were still observed when the plus-strand 
synthesis of RC-DNA was blocked.  AID and the bona fide RNA-editing enzyme A1 
caused C-to-U mutations in the viral RNA (Figs. 3 and 4). Since AID induced G-to-A 
mutations in the RC-DNA of HBV, it also deaminates minus-strand DNA (Figs. 1B 
and 2D). These results indicate that AID can deaminate both the viral RNA and the 
single-stranded DNA of HBV, suggesting the following series of events (Fig. S6). 
When AID is expressed in HBV-replicating cells, it may associate with an RNP 
complex containing pgRNA and the P protein. The RNP complex with AID may also 
attract the core protein to form a nucleocapsid, in which AID deaminates C of the 
viral RNA including pgRNA (Fig. S6C). The P protein reverse transcribes the edited 
pgRNA so that the C-to-T mutation is fixed in the minus strand of the RC-DNA.  
During synthesis of the minus-strand RC-DNA, AID may introduce further DNA 
deamination, giving rise to dG-to-dA mutations in the RC-DNA (Fig. S6D).  
Theoretically, the plus strand of RC-DNA can be deaminated, but AID is known to be 
inefficient in deaminating double-stranded DNA, which is the form in which the 
plus-strand DNA exists.   
With current experimental approaches, it is difficult for us to demonstrate the 
endogenous AID activity in our hepatic cell lines (Huh7 and HepG2), possibly 
because the AID expression level does not reach the level to cause measurable 
hypermutation.  Previous studies using clinical samples have reported that AID 
expression is induced in the liver of hepatitis patients, suggesting that AID could be 
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induced by chronic inflammation and may inhibit HBV replication in vivo (19, 33). 
Further study is required to determine the role of AID in the liver of hepatitis patients. 
It was reported that mononuclear cells such as B lymphocytes can serve as a reservoir 
for HBV (34-36). We demonstrated that a human B cell line, BL2, can support HBV 
replication after its transfection with the HBV replicon plasmid, and we found that 
endogenous AID expression introduces hypermutation in HBV (Fig. 6).  
AICDA-proficient BL2 cells produced less nucleocapsid DNA than did 
AICDA-deficient cells (Fig. 6A, right), suggesting that endogenous AID had an 
antiviral activity against HBV in the B cells, in agreement with previous studies in 
which AID was overexpressed in HBV-replicating hepatic cell lines (19, 37).   
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Materials and Methods 
Hypermutation assay 
The 3D-PCR was performed as previously described, with minor modifications (21).  
A fragment of the X gene was amplified using a nested procedure. The 3D-PCR was 
performed using a gradient program that generated 3°C–12°C gradients in the 
denaturation temperature using a thermal cycler, i.e., a MyCycler (Bio-Rad) or a 
MasterCycler Pro (Eppendorf). The initial PCR conditions were: 95°C for 5 min and 
35 cycles of 95°C for 30 s, 50°C for 30 s, and 72°C for 30 s. The second round of 
3D-PCR used 1/25 of the products from the first round as templates. The 
amplification conditions were as follows: 83°C–94 °C for 5 min, then 35 cycles of 
83°C–94°C for 1 min, 45°C for 30 s, and 72°C for 30 s, followed by 72°C for 10 min. 
The C gene fragment used for sequencing was amplified by standard PCR (94°C 
denaturation). The amplification conditions were as follows: 94 °C for 5 min, then 35 
cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 40 s, followed by 72°C for 10 
min.  
 The background mutation load due to the low fidelity of rTaq and endogenous 
APOBEC deaminases was estimated by sequencing the X gene fragment of RC-DNA 
from GFP transfectants (Figs, 1B and 3A), which showed less than 2 mutations out of 
9185 nt sequenced.  The mutation load of GFP transfectants was used as a negative 
control to determine the AID activity. rTaq error predominantly produces T-to-C and 
A-to-G mutations (38). For sequencing analysis, PCR fragments from 3D-PCR or 
standard (94°C) PCR were cloned into a T vector (Promega), and the indicated 
number of successful recombinant clones was selected randomly and sequenced using 
an ABI PRISM 3130 (Applied Biosystems). Plasmids used in this study were 
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described in Supplementary Table 1. The primer sequences are shown in 
Supplementary Table 2.  
Additional Materials and Methods information provided in the Supplementary 
Materials and Methods. 
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Figure legends  
Fig. １. AID induced frequent C-to-T mutations in nucleocapsid DNA.  HepG2 
cells were co-transfected with an AID or GFP expression vector and pHBV1.5 (Fig. 
S2A). Three days post-transfection, the nucleocapsid DNAs were purified and 
subjected to the 3D-PCR assay (A) and DNA sequencing (B). The total RNA was also 
extracted for the mutation analysis in C.  (A) The 3D-PCR assay was performed as 
described in Materials and Methods.  (B) Mutation frequency of the X gene 
segments. The X gene fragments were amplified using the standard PCR protocol 
(94C denaturation) and cloned into T vectors.  Fifty-five clone sequences were 
determined. C-to-T and G-to-A mutations were significantly increased by AID 
expression compared with GFP expression (χ2 test). (C) Mutation frequency of the X 
gene fragments amplified from reverse transcribed total RNA.  
 
Fig. 2. Stable transfection with AID also induced HBV hypermutation.  (A) 
Human (h) AID-ER, mouse (m) AID-ER, P19-ER, and mock-ER-HepG2 transfectants 
were established and transiently transfected with the pHBV1.5 replicon plasmid (Fig. 
S2A). Six hours after transfection, 1 M tamoxifen (4-OHT) was added to the 
medium to activate the ER fusion proteins. Cells were harvested 72 h after 
transfection. (B) The expression of ER fusion proteins was confirmed by Western 
blotting. (C) The 3D-PCR assay of the purified nucleocapsid DNA obtained from A. 
(D) Alignment of hypermutated HBV sequences. A PCR fragment derived from the 
83.9 °C denaturation temperature reaction shown in C (indicated by an open box) was 
excised from the agarose gel and cloned into the T vector, then six E. coli clones were 
selected randomly and their X gene segments were sequenced. The sequence 
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(GenBank accession number: X02763) from pHBV1.5 is shown at the top as a 
reference sequence. Dots in the alignment indicate identity with the reference 
sequence. (E) Mutation matrix of the X gene segments of six clones in D. 
 
Fig. 3. AID and A1 induced C-to-U mutations in the viral RNA of RNase 
H-defective HBV.  (A) Mutation matrices of the X gene segments. AID or GFP 
expression vectors with pHBV-RNase H (Fig. S2B) were transfected into Huh7 cells, 
which were then cultured for 3 days. The X gene segments from the nucleocapsid 
DNA were amplified using the standard PCR protocol (94C denaturation), and the 
mutation frequency was determined as shown in Fig. 1B. C-to-T mutations were 
significantly increased by AID expression compared with GFP (χ2 test). (B) Huh7 
cells were co-transfected with an AID or GFP expression vector and pHBV-RNase H, 
then cultured for 3 days with or without lamivudine, a reverse-transcriptase inhibitor.  
The native agarose gel electrophoresis (NAGE) and Southern blotting were used to 
detect nucleocapsid DNA in the cell lysates. Protein loading for the NAGE assay was 
determined by Western blot for the GAPDH protein.  Lamivudine treatment 
completely blocked the viral nucleocapsid DNA synthesis.  (C) Huh7 cells were 
transfected with AID, A1, A3G, or GFP expression vectors, and pPB-RNase H (Fig. 
S2E), then cultured with lamivudine for three days. After proteinase K and SDS 
treatment to release encapsidated RNA, the total RNA was extracted. Reverse 
transcription was done with (+) or without (−) reverse transcriptase (RT), and PCR 
was performed to amplify the X gene segments (left). The RT-PCR products served as 
templates for the subsequent 3D-PCR (right). The 3D-PCR showed PCR 
amplification at lower temperatures with cDNAs from AID- and A1-expressing 
samples than from GFP- and A3G-expressing samples.  (D) The PCR fragments 
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(87.8°C) in C were excised and cloned into the T vector, and 64 and 66 independent 
clones were sequenced. C-to-U mutations increased more than other mutations 
(χ2 test). 
 
Fig. 4. AID deaminated the nucleocapsid RNA.  (A) Huh7 cells were 
co-transfected with an AID or GFP expression vector and pHBV-RNase H (Fig. 
S2B), then cultured for 3 days with lamivudine. Cytoplasmic lysates were subjected to 
IP with an anti-core antibody. The flow-through (FT) and immunoprecipitated (IP) 
fractions were harvested separately.  Cytoplasmic RNA was purified from the FT and 
treated with DNase I. The IPs were pretreated with proteinase K and SDS, and the 
nucleocapsid RNA was purified. (A) RT-PCR was performed to amplify the X gene 
segments (left) with (+) or without (−) reverse transcriptase (RT). The RT-PCR 
products were subjected to 3D-PCR (right). (B) A PCR fragment from the 87.3 °C 
denaturation temperature reaction in A, was excised and cloned into the T vector, and 
50 independent clones were sequenced. The C-to-U mutation significantly increased 
compared with other mutations (χ2 test). (C) Alignment of the clones in B. The 
sequence (GenBank accession number: X02763) from pHBV1.5 is shown at the top 
as a reference sequence. Dots in the alignment indicate identity shared with the 
reference sequence.  
 
Fig. 5. AID was physically associated with a ribonucleoprotein complex of HBV 
RNA and P protein.  (A) 293T cells were transfected using FLAG-tagged A3G, 
GFP, or AID and an HBV replicon plasmid (pPB, Fig. S2C), and then cultured for 3 
days. An anti-core antibody was used to immunoprecipitate proteins from the 
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cytoplasmic lysates. The immunoprecipitated proteins (IP) were blotted using the 
antibodies indicated to detect their physical association.  The whole cell lysates 
(input) were also blotted in parallel. (B) Huh7 cells were co-transfected with an AID 
or GFP expression vector and pPB, then cultured for 3 days. Co-IP using the anti-core 
antibody and immunoblotting were performed as described in A.  The crude 
cytoplasmic lysate before IP was used as the input control. (C) Double-stable cell 
lines expressing HBV and AID (or GFP) were established in HepG2 (see Materials 
and Methods). IP was performed as described in A. The crude cytoplasmic lysate 
before IP was used as the input control. (D) 293T cells were co-transfected with each 
expression vector as indicated and cultured for 3 days.  Mock: pcDNA3tag1A. 
Anti-FLAG agarose beads were used to immunoprecipitate the FLAG-P protein. 
Whole-cell lysates were blotted in parallel (input). (E) Huh7 cells were co-transfected 
with an AID expression vector and pPB, then cultured for 3 days. Cytoplasmic lysate 
was prepared, and IPs (with anti-AID antibody or control IgG) were performed. The 
IP fractions were analyzed by RT-PCR (left) and Western blotting (right). The crude 
cytoplasmic lysate before IP was used as the input control. RNAs were extracted from 
the IP fraction and crude lysate, and RT-PCR was performed (left). RT-PCR detected 
the specific amplification of HBV RNA in the anti-AID IP fraction (RT+).  
 
Fig. 6. Endogenous AID induced HBV hypermutation in B cells.  BL2 (human B 
cell line) cells were transfected with the replicon plasmid (pPB), and nucleocapsid 
formation and hypermutation were determined at 3 days post-transfection.  The GFP 
expression vector was also transfected at the same time. (A) BL2 cells were 
transfected using pPB or the pPB-P replicon plasmid (Fig. S2C and S2D), and 
nucleocapsid formation in the cytoplasmic lysates was assessed using the NAGE 
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assay. Western blotting of GFP and GAPDH was also conducted to estimate the 
transfection efficiency and protein loading. P-protein-dependent nucleocapsid DNA 
production was detected (left) by the NAGE assay. At right, AICDA +/+ and −/− BL2 
cells were transfected with pPB, while nucleocapsid formation and AID and GFP 
expression were determined the same way as on the left.  (B) The nucleocapsid 
DNAs (in A, right side) were purified and subjected to the 3D-PCR assay. (C) 
Mutation matrices of the X gene segments in the nucleocapsid DNA. The PCR 
fragments amplified by the standard PCR protocol (94 °C denaturation) were 
sequenced. C-to-T and G-to-A mutations were significantly increased in AICDA +/+ 
compared with AICDA -/- BL2 cells (χ2 test). 
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Supplementary Materials and Methods 
Cell culture and transfection 
Cells (HepG2, Huh7, and 293T) and their transfectants were grown and maintained in 
Dulbecco’s modified Eagle’s medium (DMEM; Sigma) containing 10% fetal bovine 
serum, 100 U/mL penicillin, and 100 mg/mL streptomycin.  Plasmids were 
transfected into Huh7, HepG2, and 293T cells using CalPhos (Clontech) or Fugene 6 
(Roche), according to the manufacturer’s instructions.  AICDA-proficient and 
-deficient BL2 cells were cultured and transfected by electroporation using a 
Nucleofector II (Lonza), as previously described (11) .  
Expression vectors  
The HBV replicon plasmid (pPB) contains 1.04 copies of the HBV genomic DNA and 
expresses pgRNA under control of the CMV promoter (Fig. S2C) (31).  The pPB-P 
replicon plasmid (Fig. S2D) was produced through a four-base insertion at the EcoRI 
site in the P gene of pPB. Another HBV replicon plasmid (pHBV1.5, Fig. S2A) 
contains 1.5 copies of the HBV genomic DNA and expresses pgRNA under the 
control of a pre-core promoter (20).  The pHBV-RNase H replicon plasmid (Fig. 
S2B) was made by introducing a D737V mutation into the P gene from pHBV1.5 
using a GeneTailor site-directed mutagenesis kit (Invitrogen) (27).  For detailed 
information about the vectors, see Supplementary Table 1.  Probes were labeled and 
Southern blotting signals were developed using an AlkPhos direct labeling system 
(Amersham).  Further information on the vectors and primers used in this study are 
provided in the Supplementary Tables. 
Immunoprecipitation and Western blotting 
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Cells were lysed using a buffer containing 50 mM Tris-HCl (pH 7.0), 20 mM 
NaCl, 1% NP-40, 1 mM EDTA, 2% glycerol, and a proteinase inhibitor cocktail 
(Roche).  After centrifugation, the supernatants were incubated with the antibodies 
indicated and protein G sepharose (GE Healthcare).  Anti-FLAG agarose beads (M2, 
Sigma) were used to immunoprecipitate FLAG-tagged proteins.  Western blotting 
was performed using a standard method, and signals were detected with an LAS1000 
Imager System (Fuji Film).  The antibodies used in this study were as follows: rabbit 
anti-GAPDH (G9545, Sigma), mouse anti-FLAG (M2, Sigma), rabbit anti-core 
(B0586, Dako), rabbit anti-ER (sc-534, Santa Cruz), rabbit anti-GFP (Clontech, 
632376), rat monoclonal anti-AID (eBioscience, 14-5959), anti-rat Igs HRP (Jackson 
ImmunoResearch, 712-035-153), anti-rabbit Igs-horseradish peroxidase (HRP) 
(ALI3404, eBiosource), and rabbit and mouse IgG Trueblot (eBioscience).  
 
Establishment of stable transfectants 
A stable line of HBV-expressing HepG2 cells was established using a standard 
method (2).  Briefly, HepG2 cells were transfected with linearized pPB, and G418 
drug selection was performed with limiting dilution. Of the resulting transfectants, a 
cell line with a high level of nucleocapsid DNA production was chosen from the 
G418-resistant clones.  Human AID-ER-, mouse AID-ER-, P19-ER-, or 
Mock-ER-expressing HepG2 cells (Fig. 2) were produced by retrovirus-mediated 
gene transduction.  In Fig. 5C, AID and GFP were introduced into the 
HBV-expressing HepG2 cells by retrovirus-mediated gene transduction.  The 
inducible activation of the AID-ER fusion protein by tamoxifen (4-OHT, 1 M) 
addition and retroviral gene transduction have been described (10, 23). 
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Establishment of a stable line of HBV-expressing Huh7 cells (7T7-8)   
Stable transfectants were established as described previously (2).  Briefly, Huh7 cells 
were transfected with pTETt-TAKzeo (a tetracycline activator expression vector, 
TET-off system) and subjected to limiting dilution with a zeocin selective medium.  
One clone (named 7T7) was chosen because of its good tetracycline activator 
expression. The 7T7 cells were transfected with an HBV replicon vector 
(pHBV1.2dsTETbsr), which expresses 1.2 copies of HBV genomic RNA under the 
control of a tetracycline promoter, and cloning was achieved by limiting dilution with 
blasticidin selection.  pHBV1.2dsTETbsr has a stop codon in the S gene that does 
not affect the P gene reading frame, so Huh7 cells did not secrete virions, but 
accumulated HBV transcripts and nucleocapsids. 
RT-PCR 
Total RNA was extracted using a phenol-based RNA extraction reagent, Trisure 
(Bioline).  The purified total RNA was digested further using DNase I (Takara) to 
eliminate the transfected plasmids, and purified again with Trisure.  In the RT-PCR 
analysis, 1 g of total RNA was treated with amplification grade DNase I (Invitrogen), 
then reverse transcribed with oligo(dT) using SuperScript III (Invitrogen). 
Semi-quantitative RT-PCR 
Total RNA was extracted using Trisure (Bioline), treated with DNase I (Takara) to 
eliminate transfected plasmids, and re-purified with Trisure.  In the qRT-PCR 
analysis, 1 g of the total RNA was treated with amplification grade DNase I 
(Invitrogen) and reverse transcribed with an oligo-dT or random primer using 
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SuperScript III (Invitrogen).  The cDNA was amplified using specific primers for 
A3A, A3B, A3C, A3DE, A3F, A3G, A3H, ADAR1, A1, A2, and -actin. 
RNA immunoprecipitation 
Cells were lysed with IP buffer (50 mM Tris-HCl [pH 7.0], 20 mM NaCl, 1% NP-40, 
1 mM EDTA, 2% glycerol, and protease inhibitor cocktail).  Immunoprecipitation 
was performed with protein G sepharose (Amersham) for 4 h at 4 °C in a 
chromatography column (BioRad) using anti-AID or control IgG antibodies.  Protein 
G was washed twice each with cooled IP buffer and PBS.  The immunoprecipitated 
RNA and proteins were eluted from the protein G sepharose using elution buffer (100 
mM Tris-HCl [pH 8.0], 10 mM EDTA, and 1% SDS), and the RNA was purified 
further with Trisure. The immunoprecipitated RNA was treated with DNase I and 
re-purified with Trisure. The obtained RNAs and proteins were analyzed by RT-PCR 
and immunoblotting, respectively.   
Native agarose gel electrophoresis (NAGE) assay 
The NAGE assay has been described previously (30).  Briefly, crude extracts 
containing HBV nucleocapsid particles were loaded onto an agarose gel and subjected 
to electrophoresis to separate intact nucleocapsid particles.  The nucleocapsid 
particles in the gel were then denatured using an alkaline condition and transferred 
onto a nitrocellulose membrane (Roche).  The nucleocapsid DNA and core protein 
were detected by Southern and Western blotting using a double-stranded HBV DNA 
probe that spanned the entire viral genome, and the anti-core antibody, respectively.  
The RC-DNA was purified from the cytoplasmic lysate by the following series: 
DNase I digestion to eliminate transfected plasmids, proteinase K and SDS digestion, 
phenol-chloroform extraction, and isopropanol precipitation.  
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Nucleocapsid pgRNA purification 
Cells were treated with lamivudine (50-100M) to inhibit HBV DNA synthesis and 3 
days later were lysed with IP buffer (50 mM Tris-HCl [pH 7.0], 20 mM NaCl, 1% 
NP-40, 1 mM EDTA, 2% glycerol, and protease inhibitor cocktail).  To isolate HBV 
nucleocapsids, immunoprecipitation was performed using protein G sepharose with an 
anti-core antibody for 4–6 h at 4°C in a chromatography column.  The unbound 
RNA was recovered from the flow-through by Trisure purification and was treated 
further with DNase I.  The immunoprecipitates were washed twice each with cooled 
IP buffer and PBS.  The immunoprecipitates were eluted from protein G using 
elution buffer (100 mM Tris-HCl [pH 8.0], 10 mM EDTA, and 1% SDS) and treated 
further with proteinase K and SDS for 5–10 h at 37°C.  Trisure was used to terminate 
the reaction directly and to purify the nucleocapsid RNA.  The obtained RNAs were 
pretreated with DNase I and analyzed by RT-PCR or 3D-PCR.  
 
Supplementary figure legends 
Fig. S1. Schematic diagram of the HBV viral life cycle and outcomes of 
deamination in the RC-DNA plus strand.  The HBV viral life cycle, experimental 
approaches to stopping the viral life cycle, possible targets for AID/APOBEC 
deaminases, and expected outcomes of deamination are depicted.  (A) The P protein 
binds epsilon in pgRNA and forms an RNP complex in HBV-replicating cells.  (B) 
The HBV RNP complex is encapsidated to form a nucleocapsid.  (C) The P protein 
reverse transcribes nucleocapsid pgRNA to produce minus-strand DNA. This step is 
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blocked by lamivudine.  (D) The P protein digests the pgRNA by its RNase H 
activity.  In RNase H-defective mutant HBV, the viral life cycle stalls in the 
RNA/DNA-hybrid phase.  Deamination in the minus-strand DNA is detected as a 
G-to-A mutation by DNA sequencing.  (E) The P protein synthesizes plus-strand 
DNA to complete the production of RC-DNA.  RNA deamination (in A and B) and 
plus-strand DNA deamination result in the accumulation of C-to-T mutations in the 
nucleocapsid DNA.  (+): plus-strand DNA. (-): minus-strand DNA. 
Fig. S2. Schematic diagram of the wild-type and mutant replicon plasmids.  The 
partially redundant HBV genomic DNA is depicted as a black box, while the positions 
of the 5’- and 3’-epsilon are shown as pinheads.  The corresponding open reading 
frames of the core (C), P, S, and X genes are shown as open boxes.  The domain 
structure (terminal protein: TP, spacer, polymerase, RNase H) of the P protein is 
indicated within the P gene, separated by dotted lines.  The positions of introduced 
point mutations are shown as an open triangle.  The pPB (pPB, pPB-RNase H, and 
pPB-P) replicon plasmids transcribed viral genomic RNA (pgRNA) through the 
CMV promoter, whereas pHBV (pHBV1.5 and pHBV-RNase H) transcribed pgRNA 
through the viral pre-core promoter; the positions of these promoters are indicated by 
arrows. 
Fig. S3. AID induced HBV hypermutation in a stable HBV line.  (A) A schematic 
representation of 7T7-8 cells (see Supplementary Materials and Methods).  A stable 
HBV transfectant of Huh7 was established and designated 7T7-8.  The induced 
expression of nucleocapsid DNA in 7T7-8 cells in the absence of tetracycline was 
demonstrated by Southern blotting of the NAGE assay (bottom).  Zeo R: 
zeocin-resistance gene; bsd R: blasticidin-resistance gene.  (B) 7T7-8 cells were 
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transfected with AID-GFP, HA-A3G, or GFP vectors and cultivated in the absence of 
tetracycline for 3 days.  Nucleocapsid DNAs were purified and used as templates in 
the 3D-PCR assay.  AID and A3G expression induced hypermutation in the 
RC-DNA. 
Fig. S4. RNase H-defective HBV did not produce the plus-strand DNA of 
RC-DNA. Three days after the transfection of 293T cells with HBV replicon plasmids 
(pPB and pPB-RNase H), the nucleic acids were purified from nucleocapsids, 
incubated with or without RNase H, and subjected to Southern blotting.  The pPB 
plasmid was loaded in the right-hand lane as a control.  The nucleocapsid nucleic 
acids from wild-type HBV produced a band corresponding to the relaxed circle (lane 
1).  RNase H digestion splits the signal of the relaxed circle in lane 1 into two bands 
(upper: RC-DNA; lower: single-stranded DNA) (lane 2).  In contrast, the nucleic 
acids extracted from RNase H-defective HBV (lane 3) produced a signal similar to 
lane 1, although the signal intensity was lower than that of wild-type HBV.  After 
digestion with RNase H in vitro, only the signal corresponding to single-stranded 
DNA was observed, indicating that plus-strand DNA synthesis was suppressed in the 
RNase H mutant HBV.  The interpretation is depicted below.  Dotted lines: 
pgRNA.  Solid lines: DNA.  (+): plus-strand DNA.  (-): minus-strand DNA. 
Fig. S5. Expression profile of the APOBEC family in BL2 cells.  Total RNA was 
extracted from AICDA+/+ and -/- BL2 cells, and semi-quantitative RT-PCR was 
performed to assess the expression of APOBEC deaminases.  The cDNAs were 
serially diluted, and the expression of APOBEC deaminases was compared between 
the AICDA+/+ and -/- BL2 cells.  ADAR1 and -actin expression were used as 
controls. 
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Fig. S6. A proposed model for AID-mediated hypermutation of the HBV genome.  
(A) HBV RNP complex formation.  (B) AID can associate with P protein and 
pgRNA.  (C) The RNP complex containing AID is packaged with the core protein 
and the encapsidated AID protein deaminates pgRNA.  (D) The P protein reverse 
transcribes the edited pgRNA to produce minus-strand DNA.  During minus-strand 
DNA synthesis, AID further deaminates the minus-strand DNA.  (E) AID also 
induces C-to-U conversion in the plus-strand DNA.  Thus, AID causes C-to-T and 
G-to-A mutations in RC-DNA by acting on three forms of the viral genome.  (+): 
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Table S1. Vector list 
 
 
    
 
Name Description 
 pHBV1.5 A replication-competent HBV replicon plasmid, in which the HBV pgRNA is driven 
by viral pre-core promoter (20). 
 
pHBV-ΔRNaseH 
A D737V mutation in the P gene  has been shown to specifically delete RNaseH 
activity from the P protein (27). Thus a point mutation to make the D737V was 
introduced in pHBV1.5 using the GeneTailor site-directed mutagenesis kit 
(Invitrogen). 
 pPB A replication-competent HBV replicon plasmid, in which the HBV pgRNA is driven 
by CMV promoter (31). 
 
pPB-ΔP 
An EcoRI site that locates in the middle of P gene in pPB was digested by EcoRI, 
treated with Klenow enzyme and ligated to creat 4 bases insertion in EcoRI site. This 
insertion results in a frame shift mutation in the spacer region of P gene. 
 pPB-ΔRNaseH An EcoRV/SacII P gene fragment containing D737V mutation was replaced with 
corresponding fragment in pPB. 
 pCMV-AID A DNA fragment of AID from pFBhAID (10) was replaced with one for GFP gene in 
pGFP2C3 (Biosignal Packard). 
 pCMV-hAID-GFP previously mentioned (10). 
 
pCMV-A1 
IRES-EGFP gene in pIRES2-EGFP (Clontech) was deleted by SmaI/Bsp1407I 
digestion to make a CMV expression vector (designated pCMVneo). Human 
APOBEC1 ORF was inserted in multiple cloning site of pCMVneo. 
 pFLAG-P HBV P protein ORF in pHBV1.5 was amplified by PCR and cloned into pCMV-3Tag-
1A (Invitrogen) to make the vector that can express the FLAG-tagged P-protein. 
 hAID-pFB-ires-puro Human AID ORF was inserted into multicloining site of retrovirus vector pFB-ires-
puro. This was used for establishment of AID expressing HepG2 cells. 
 GFP-pFB-ires-puro Human EGFP ORF was inserted into multicloining site of retrovirus vector pFB-ires-
puro. This was used for establishment of GFP expressing HepG2 cells. 
 
pFERp 
pFB-AIDER-ires-puro retrovirus vector was described previousely (10).  AID gene in 
pFB-AIDER-ires-puro was replaced with a synthetic DNA linker containing 
mutlicloning site to make a mock retrovirus vector and designated pFERp. 
 
mock-pFERp 
Two oligonucleotides (5'-AATTCTAGCACCATGGCTAAG-3', 5'-
GATCCTTAGCCATGGTGCTAG-3') containing an in-frame ATG were hybridized 
and inserted in an EcoRI/BamHI site of the pFERp retroviral vector. After puromysin 
selection, this retrovirus vector stably expresses flag-ER chimerica protein. This is 
used as a mock control expressing flag-ER protein alone. 
 pFB-mAIDER-ires-puro previously mentioned (10). 
 hAID-pFERp hAID was inserted in pFERp to make a retrovirus vector expressing hAIDER-ires-puro 
mRNA. 
 p19-pFERp p19-AID was inserted in pFERp to make a retrovirus vector exprssing p19ER-ires-puro 
mRNA. 
 pFLAG-GFP A GFP2 ORF fragment in pGFP2N3 (Biosignal Packard) is inserted into 
pCMV3Tag2B (Invitrogen).  
 pFLAG-A3G Human A3G ORF was cloned into pcDNA3Tag1A (Invitrogen). 
 pcDNA3/HA-A3G kindly gifted by Dr. Takaori in Kyoto university . 
 pTETtTAK zeo previously mentioned (2, 10) 
 pTet-splice-bsr Blasticidin resistant gene expression cassette was inserted in BstXI site in pTET-splice 
(GIBCO). 
 pHBV1.2dsTet-bsr2 1.2 copy of HBV genomic DNA from pHBV1.5 which contains a stop codon in S open 
reading frame was inserted into multiple cloning  (SalI/ClaI ) of pTet-Splice-bsr.   
 
     
   
Table S2. Primer list 
   
    
Name     Sequence (5'→3') 
HBV X segement 1st fwd 
 
  CGGAAATATACATCGTTTCCAT 
HBV X segment 1st rev 
 
  AAGAGTYYTYTTATGTAAGACYTT 
HBV X segment 2nd fwd 
 
  ATGGCTGCTARGCTGTACTGCCAA 
HBV X segment 2nd rev 
 
  AAGTGCACACGGAYYGGCAGAT 
HBV C segment fwd 
 
  CATGTCCCACTGTTCAAGCCT 
HBV C segment rev 
 
  GAAACCACAATAGTTGCCTGATC 
A3A fwd 
 
  ATGGCATTGGAAGGCATAAG 
A3A rev 
 
  CAAAGAAGGAACCAGGTCCA 
A3B fwd 
 
  TTCGAGGCCAGGTGTATTTCA 
A3B rev 
 
  CAGAGATGGTCAGGGTGACA 
A3C fwd 
 
  CAACGATCGGAACGAAACTT 
A3C rev 
 
  TATGTCGTCGCAGAACCAAG  
A3D fwd 
 
  ACCCAAACGTCAGTCGAATC 
A3D rev 
 
  GCTCAGCCAAGAATTTGGTC  
A3F fwd 
 
  GAAACACAGTGGAGCGAATG 
A3F rev 
 
  GAAATGGGGCTCTGATGAAAG 
A3G fwd 
 
  GGTCAGAGGACGGCATGAGA 
A3G rev 
 
  GCAGGACCCAGGTGTCATTG 
A3H fwd 
 
  CCCGCCTGTACTACCACTGG   
A3H rev 
 
  GGGTTGAAGGAAAGCGGTTT 
                          ADAR1 fwd 
 
  CGTGCTATTTGCTGTCGTGT  
                          ADAR1 rev 
 
  TAGTCACGGGCAGCTTTCTT 
                                 A1 fwd 
 
  GAAGAATCGAACCCTGGGAGTTT 
                                A1 rev 
 
  CCCAGGTGGGTAGTTGACAAA 
                               A2 fwd 
 
  GGTGGGTCGACTCTTCATGTGG 
                              A2 rev 
 
  GGGCCTTGTCCAGTATGATTGGT 
β-Actin fwd 
 
  GACCTGACTGACTACCTCATGAAGA 
β-Actin rev 
 
  GGGGCCGGACTCGTCATACTCCTGC 
HPRT fwd 
 
  GCCCTGGCGTCGTGATTAGT 
HPRT rev     CGAGCAAGACGTTCAGTCCTGTC 
   
Y represents C and T. 
   
R represents G and A. 
    
 
